And then, when you move all the way up to tirzepatide, which is the first and only dual agonist, it's actually a GLP-1 receptor agonist, GIP agonist, you're now talking about 15 to 25% body weight loss, which- Advertisement John Horton: that's a lot
Retrieved from Congressional Research Service
Oxidative stress and damage is proven to be a large contributor to aging and deterioration in physiological function
Frequency and Timing To mimic your bodys natural pulsatile GH release , timing matters
Key takeaways Fatigue and low energy often has multiple causes, including nutrient deficiencies, inadequate sleep, lack of physical activity, and more
Notably, tirzepatide (Zepbound) was not approved for weight management in patients with overweight or obesity until shortly before the patient-identification window closed, resulting in most patients in the tirzepatide cohort receiving Mounjaro, which was assumed to be used off-label for chronic weight management in the absence of T2DM
)
